Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

07:32
12/12/18
12/12
07:32
12/12/18
07:32

Neurocrine says valbenazine did not meet primary endpoint in Phase IIb study

Neurocrine Biosciences announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale in children and adolescents with moderate to severe Tourette syndrome. The types of treatment emergent adverse events observed in this trial were consistent with those seen in other valbenazine studies. "We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options. This study was well-conducted with a placebo response as expected, but the treatment effect of valbenazine was lower than we had anticipated," said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "We would like to thank the patients, caregivers and investigators for their participation in this study. We will further analyze the data to determine the next steps for valbenazine in Tourette syndrome."

NBIX Neurocrine
$85.72

-0.14 (-0.16%)

11/21/18
ADAM
11/21/18
INITIATION
Target $111
ADAM
Buy
Neurocrine initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated Neurocrine with a Buy rating as he said the company is one of the few where a product launch exceeded expectations. He said he is guardedly optimistic heading into Phase 2b data for Ingrezza in pediatric Tourette syndrome and with the stock's recent pullback, he sees an attractive entry point. He also thinks the pullback could cause investors to look at Neurocrine to be involved in industry consolidation. Kulkarni set a $111 price target on Neurocrine shares.
11/15/18
BARD
11/15/18
NO CHANGE
Target $131
BARD
Outperform
Neurocrine elevated to Fresh Pick, FAERS fears unwarranted, says Baird
Baird analyst Brian Skorney elevated Neurocrine to Fresh Pick and said to take advantage of the unwarranted fear caused by the FDA's FAERS update. The analyst said the update was a regular update to their database and it did yield a numerically higher number of patient deaths. However, he said this is typical because as the number of Ingrezza prescriptions increase, so will the number of incidents. He believes this caused an overreaction and investors should take advantage of the buying opportunity. Skorney reiterated his Outperform rating and $131 price target on Neurocrine shares.
11/15/18
JEFF
11/15/18
NO CHANGE
Target $131
JEFF
Buy
Jefferies says buy Neurocrine after yesterday's 'unwarranted' selloff
Jefferies analyst Biren Amin tells investors to buy shares of Neurocrine Biosciences after hosting a dinner with management. Management shared thoughts on the Ingrezza launch and dispelled recent safety concerns, noting the company rigorously reports the majority of adverse events found in the FDA database and that none of the 88 deaths reported are due to Ingrezza, Amin tells investors in a research note. Further, the analyst thinks the risk/reward on shares into the December Tourettes data is "significant to the upside." Amin views yesterday's selloff as "unwarranted" and keeps a Buy rating on Neurocrine with a $131 price target. The stock closed yesterday down 13%, or $13.37, to $86.13.
11/13/18
LEER
11/13/18
INITIATION
Target $110
LEER
Market Perform
Neurocrine initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Neurocrine with a Market Perform and $110 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Neurocrine, Goodman believes Ingrezza should be a significant product for TD/TS but consensus sales expectations are already high.

TODAY'S FREE FLY STORIES

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

, AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
Breaking Hot Stocks news story on Charles Schwab, TD Ameritrade »

Charles Schwab drops 1%…

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:42
11/21/19
11/21
05:42
11/21/19
05:42
Hot Stocks
Breaking Hot Stocks news story on TD Ameritrade, Charles Schwab »

TD Ameritrade jumps 13%…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:41
11/21/19
11/21
05:41
11/21/19
05:41
Periodicals
Charles Schwab in talks to acquire TD Ameritrade, CNBC reports »

Charles Schwab (SCHW) is…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$189.85

7.64 (4.19%)

05:40
11/21/19
11/21
05:40
11/21/19
05:40
Downgrade
RH rating change  »

RH downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$8.62

-0.03 (-0.35%)

05:39
11/21/19
11/21
05:39
11/21/19
05:39
Downgrade
MacroGenics rating change  »

MacroGenics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

, ABBV

AbbVie

$87.20

-1.82 (-2.04%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Hot Stocks
Harpoon Therapeutics, AbbVie announce licensing, option collaboration »

Harpoon Therapeutics…

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

ABBV

AbbVie

$87.20

-1.82 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

THDDY

TV Asahi

$0.00

(0.00%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Downgrade
TV Asahi rating change  »

TV Asahi downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

05:37
11/21/19
11/21
05:37
11/21/19
05:37
Downgrade
Nintendo rating change  »

Nintendo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Earnings
Breaking Earnings news story on Baozun »

Baozun sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SGSOY

SGS SA

$0.00

(0.00%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Upgrade
SGS SA rating change  »

SGS SA upgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Earnings
Baozun reports Q3 EPS 14c, consensus 14c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FUJHY

Subaru

$0.00

(0.00%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Downgrade
Subaru rating change  »

Subaru downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$55.27

-0.98 (-1.74%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Initiation
Dell Technologies initiated  »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 09

    Dec

  • 09

    Dec

PCG

PG&E

$7.14

0.29 (4.23%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Hot Stocks
PG&E begins restoring power in Napa, Sonoma counties »

As of 7 p.m., Pacific Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

DRTGF

Dart Group

$0.00

(0.00%)

05:33
11/21/19
11/21
05:33
11/21/19
05:33
Upgrade
Dart Group rating change  »

Dart Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$2.91

-0.06 (-2.02%)

05:32
11/21/19
11/21
05:32
11/21/19
05:32
Hot Stocks
Cellcom Israel announces purported class action filed against the company »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TPDKY

Topdanmark

$0.00

(0.00%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Upgrade
Topdanmark rating change  »

Topdanmark upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGL

Golden Ocean

$5.40

0.025 (0.47%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Hot Stocks
Golden Ocean announces CEO resignation, chairman Ola Lorentzon named interim CEO »

Golden Ocean announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

05:30
11/21/19
11/21
05:30
11/21/19
05:30
General news
Bond markets erase gains, »

Bond markets erase gains,…

FLNG

Flex LNG

$9.40

0.74 (8.55%)

05:29
11/21/19
11/21
05:29
11/21/19
05:29
Downgrade
Flex LNG rating change  »

Flex LNG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCEXF

Saracen Mineral

$0.00

(0.00%)

05:28
11/21/19
11/21
05:28
11/21/19
05:28
Upgrade
Saracen Mineral rating change  »

Saracen Mineral upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWE

NorthWestern

$69.93

0.53 (0.76%)

05:26
11/21/19
11/21
05:26
11/21/19
05:26
Upgrade
NorthWestern rating change  »

NorthWestern upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$164.57

0.55 (0.34%)

05:23
11/21/19
11/21
05:23
11/21/19
05:23
Recommendations
Salesforce analyst commentary  »

Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 16

    Dec

GMBXF

Grupo Mexico

$0.00

(0.00%)

05:20
11/21/19
11/21
05:20
11/21/19
05:20
Downgrade
Grupo Mexico rating change  »

Grupo Mexico downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRCX

Lam Research

$273.99

-2.65 (-0.96%)

05:19
11/21/19
11/21
05:19
11/21/19
05:19
Downgrade
Lam Research rating change  »

Lam Research downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.